News | February 05, 2022
Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore
Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021
Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021
Partnering to build biosynthesis processes and a pharmaceutical production platform
The transaction is anticipated to close in the first quarter of 2022
Ectosense’s NightOwl is a leading cloud-connected home sleep apnea test
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
Anti-malaria API facility will be operational in 15-18 months
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Subscribe To Our Newsletter & Stay Updated
